Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: IEEE Trans Biomed Eng. 2015 Aug 20;63(4):737–746. doi: 10.1109/TBME.2015.2469741

TABLE III.

Percentage of Trial Duration with at Least Two DOFs Simultaneously Active

1-DOF Target 2-DOF Target 3-DOF Target
Linear Regression Parallel Dual-Site Linear Regression Parallel Dual-Site Linear Regression Parallel Dual-Site
2 DOFs
simultaneously active * 		25.6% (± 2.19%) 6.7% (± 2.2%) 48.7% (± 1.67%) 36.3% (± 2.8%) 38.8% (± 0.78%) 29.8% (± 2.5%)
3 DOFs
simultaneously active* 		2.8% (± 0.5%) 0.2% (± 0.2%) 12.3% (± 1.3%) 2.2% (± 1.1%) 26.4% (± 3.0%) 6.27% (± 1.9%)
*

Significant difference in amount of simultaneous activity between linear regression and parallel dual-site control (p < 0.001)